Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial

BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) became the first approved treatment for patients with metastatic MCC (mMCC), based on the occurrence of durable responses in...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Immunother Cancer
Главные авторы: D'Angelo, Sandra P, Bhatia, Shailender, Brohl, Andrew S, Hamid, Omid, Mehnert, Janice M, Terheyden, Patrick, Shih, Kent C, Brownell, Isaac, Lebbé, Celeste, Lewis, Karl D, Linette, Gerald P, Milella, Michele, Georges, Sara, Shah, Parantu, Ellers-Lenz, Barbara, Bajars, Marcis, Güzel, Gülseren, Nghiem, Paul T
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2020
Предметы:
Clinical/Translational Cancer Immunotherapy
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7239697/
https://ncbi.nlm.nih.gov/pubmed/32414862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000674
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы